Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sunshine Heart Gears Up For Heart Failure Implant Pivotal Trial

This article was originally published in The Gray Sheet

Executive Summary

Firm preps for U.S. pivotal trial and European market launch in the third quarter for its minimally invasive, extra-aortic balloon counter-pulsation system for moderate to severe heart failure.

You may also be interested in...



People Briefs: InVivo Therapeutics CEO Resigns; CVPath Institute, Harvard Bioscience Appoint New CEOs

InVivo Therapeutics Holdings Corp. chairman and CEO resigns. CVPath Institute and Harvard Bioscience get new CEOs. Cook Medical appoints VP to lead its aortic intervention clinical division. Sunshine Heart names chief medical officer.

News In Brief

Conmed snaps up Viking Systems. Sunshine Heart’s C-Pulse heart assist device is approved in Europe. KCI patent appeal puts ball back in S&N’s court. More news briefs.

Heart Failure Devices: Raising Roadblocks To Readmission

A new Medicare cost-control program aimed at reducing costly hospital readmissions has heart failure squarely in the cross-hairs, and the consequences could mean hundreds of thousands of dollars in lost Medicare revenue for hospitals that fail to meet the new readmission standards. As a result, providers are scrambling to implement programs to assess and reduce heart failure readmissions, and a growing number of device companies are touting a variety of technologies they believe could help them achieve that goal.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031262

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel